D evelopment of a patient decision aid for type 2 diabetes mellitus for patients not achieving glycemic control on metformin alone

被引:17
作者
Shillington, Alicia C. [1 ]
Col, Nananda [2 ]
Bailey, Robert A. [3 ]
Jewell, Mark A. [1 ]
机构
[1] EPI Q Inc, Oak Brook, IL 60523 USA
[2] Shared Decis Making Resources, Georgetown, ME USA
[3] Janssen Sci Affairs LLC, Raritan, NJ USA
来源
PATIENT PREFERENCE AND ADHERENCE | 2015年 / 9卷
关键词
patient decision aid; shared decision-making; type; 2; diabetes; ADHERENCE; PHYSICIANS; FRAMEWORK; OUTCOMES; QUALITY; HEALTH; IMPACT;
D O I
10.2147/PPA.S82555
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: To describe the process used to develop an evidence-based patient decision aid (PDA) that facilitates shared decision-making for treatment intensification in inadequately controlled type 2 diabetes mellitus (T2DM) consistent with International Patient Decision Aids Standards. Methods: A PDA was developed by a multidisciplinary steering committee of clinicians, patient advocate, nurse, certified diabetes educators, and decision scientist, using a systematic development process. The process included defining the PDA scope and purpose, outlining the framework, content creation, and designing for integration into clinical practice. This was accomplished through a review of the literature and publically available educational materials and input from practicing clinicians and patients during development and iteratively refining content based on input. Patients with poorly controlled T2DM on metformin considering additional medication assessed the PDA during a pilot. Results: Testing identified six preference-sensitive domains important for choosing T2DM treatment: degree of glycemic response, avoiding weight gain, hypoglycemia risk and other adverse events, avoiding injections, convenience of dose administration, blood glucose monitoring, and cost of therapy. Patient feedback guided content revision. Treatment options were offered after presenting medication class risk-benefit information and eliciting patient values, goals, and preferences. The PDA received the highest International Patient Decision Aids Standards global score to date, 88/100, with 100% of criteria fully met for the following dimensions: development process, disclosures, evaluation process, evidence quality, guidance for users, information quality, language/readability, testing, and eliciting patient values. Conclusion: A PDA was developed to help T2DM patients make decisions regarding medication choice. This approach may be applicable to other chronic conditions.
引用
收藏
页码:609 / 617
页数:9
相关论文
共 50 条
  • [21] Value of Patient-Centered Glycemic Control in Patients with Type 2 Diabetes
    René Rodríguez-Gutiérrez
    Juan Manuel Millan-Alanis
    Francisco J. Barrera
    Rozalina G. McCoy
    Current Diabetes Reports, 2021, 21
  • [22] Depressive symptoms in Type 1 and Type 2 Diabetes Mellitus and its relationship with glycemic control
    Massano-Cardoso, Ilda
    Daniel, Fernanda
    Rodrigues, Vitor
    Galhardo, Ana
    REVISTA PORTUGUESA DE INVESTIGACAO COMPORTAMENTAL E SOCIAL, 2020, 6 (01): : 40 - 49
  • [23] Patient Assessment of Family Function, Glycemic Control and Quality of Life in Adult Patients With Type 2 Diabetes and Incipient Complications
    Bennich, Birgitte B.
    Munch, Lene
    Egerod, Ingrid
    Konradsen, Hanne
    Ladelund, Steen
    Knop, Filip K.
    Vilsboll, Tina
    Roder, Michael
    Overgaard, Dorthe
    CANADIAN JOURNAL OF DIABETES, 2019, 43 (03) : 193 - 200
  • [24] Value of Patient-Centered Glycemic Control in Patients with Type 2 Diabetes
    Rodriguez-Gutierrez, Rene
    Millan-Alanis, Juan Manuel
    Barrera, Francisco J.
    McCoy, Rozalina G.
    CURRENT DIABETES REPORTS, 2021, 21 (12)
  • [25] Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea
    Ji, L.
    Han, P.
    Liu, Y.
    Yang, G.
    Van, N. K. Dieu
    Vijapurkar, U.
    Qiu, R.
    Meininger, G.
    DIABETES OBESITY & METABOLISM, 2015, 17 (01) : 23 - 31
  • [26] Effect of metformin monotherapy and dual or triple concomitant therapy with metformin on glycemic control and lipid profile management of patients with type 2 diabetes mellitus
    Lin, Yan-Yu
    Weng, Shuen-Fu
    Hsu, Chung-Huei
    Huang, Chen-Ling
    Lin, Yu-Pei
    Yeh, Min-Chun
    Han, A-Young
    Hsieh, Yu-Shan
    FRONTIERS IN MEDICINE, 2022, 9
  • [27] Improvement of Dietary Quality with the Aid of a Low Glycemic Index Diet in Asian Patients with Type 2 Diabetes Mellitus
    Nisak, Mohd Yusof Barakatun
    Abd Talib, Ruzita
    Norimah, A. Karim
    Gilbertson, Heather
    Azmi, Kamaruddin Nor
    JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 2010, 29 (03) : 161 - 170
  • [28] Effect of coaching on glycemic control among type 2 diabetes mellitus patients: A literature review
    Irnawan, Sri Marnianti
    Syahrul, Syahrul
    ENFERMERIA CLINICA, 2020, 30 : 158 - 162
  • [29] Effect of Zinc Supplementation on Glycemic Control in Newly Diagnosed Patients With Type 2 Diabetes Mellitus
    Chhina, Gurpreet S.
    Chhabra, Ajay
    Luthra, Sumedh R.
    Khattar, Saloni
    Singh, Priyanka
    Luthra, Shivansh
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (09)
  • [30] Impact of COVID-19 lockdown on glycemic control in patients with type 1 and type 2 diabetes mellitus: a systematic review
    Eberle, Claudia
    Stichling, Stefanie
    DIABETOLOGY & METABOLIC SYNDROME, 2021, 13 (01)